



Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit

September 22, 2022

DURHAM, N.C.--(BUSINESS WIRE)--Sep. 22, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based *ex vivo* allogeneic CAR T and *in vivo* gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.

Details for the company presentation are as follows:

Date: Friday, September 30, 2022

Time: 2:00 PM ET

Location: Lotte New York Palace Hotel

The presentation will be available via a recorded webcast accessible on Precision's website in the Investors section under Events & Presentations: <https://investor.precisionbiosciences.com/events-and-presentations>. An archived replay will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple *ex vivo* "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20220922005120/en/>

Investor Contact:

Mei Burris

Director, Investor Relations & Finance

Mei.burris@precisionbiosciences.com

Media Contact:

Maurissa Messier

Senior Director, Corporate Communications

Maurissa.Messier@precisionbiosciences.com

Source: Precision BioSciences, Inc.